pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

361 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1024Endpoints776BioPharma Dive297BioSpace214Fierce Biotech203onclive165raps74globenewswire health73
therapy area
allOncology6025Rare Disease1434Cardiology1089Hematology1024Immunology1000Vaccines901Pulmonology899
  • InstallatørGruppen reports insider share transaction involving board members' associate
    InstallatørGruppen A/S has filed a Market Abuse Regulation (EU) No. 596/2014 notification under article 19, disclosing a recent share transaction. The transaction was executed by Absalon Holdings…
    globenewswire health · 14d agoRegulatoryNeutral↗ source
  • InstallatørGruppen reports share transaction by board linked entity Absalon Holdings
    InstallatørGruppen A/S filed a notification under the EU Market Abuse Regulation, article 19, to disclose a share transaction involving a person discharging managerial responsibilities and their cl…
    globenewswire health · 14d agoRegulatoryNeutral
← prev
page 6 of 15
next →
fda recalls47
fda medwatch37
fda press28
Psychiatry & CNS712
Ophthalmology421
Endocrinology & Metabolism380
Pain373
Infectious Disease353
↗ source
  • Eli Lilly posts $23 B Q2 revenue, beats forecasts as Foundayo lags behind Novo's oral GLP-1
    Eli Lilly reported second‑quarter revenue of $23 billion, a 48% increase from the prior year and well above analysts' expectations. The strong top‑line helped the company deliver a sizable earnings…
    BioSpace · 15d agoEarningsNeutral↗ source
  • Lilly and FDA clash over retatrutide classification as company nears submission
    Eli Lilly is preparing to file its obesity drug candidate retatrutide for approval while a legal dispute with the FDA over the drug's classification intensifies. The agency has concluded that reta…
    BioSpace · 15d agoRegulatoryNeutral↗ source
  • Lilly's Foundayo obesity pill posts $98 million Q2 sales, trails Novo's Wegovy
    Eli Lilly introduced its oral obesity treatment Foundayo after receiving FDA approval in April 2025. The drug entered the market in the second quarter of 2026, marking Lilly's first foray into an o…
    BioSpace · 15d agoNegative readoutNeutral↗ source
  • Analysts spot several biotech firms as likely M&A targets amid rising pharma deal activity
    Pharma companies are actively looking for acquisition opportunities, and analysts have identified a handful of biotech firms that could be next in line for buyouts. Recent transactions have center…
    BioSpace · 15d agoDealNeutral↗ source
  • AstraZeneca and BMS deny merger talks, Reuters says no deal
    Reuters reported that rumors of a merger between AstraZeneca and Bristol Myers Squibb have been dismissed. A senior source close to the matter told Reuters there is no deal and no discussions betw…
    BioSpace · 15d agoDealNeutral↗ source
  • Over a third of biotech and pharma workers stay in their jobs for health insurance, poll shows
    A recent BioSpace LinkedIn poll and a joint study by West Health and Gallup found that a significant share of biotech and pharma employees remain in their current roles primarily to keep health ins…
    BioSpace · 15d agoNegative↗ source
  • FDA advisory committee meetings sow confusion, threaten trust with rare disease developers
    The Food and Drug Administration has been working to repair its relationship with rare-disease drug makers and patient groups since former commissioner Marty Makary left three months ago. Last wee…
    BioSpace · 15d agoRegulatoryNegative↗ source
  • Gilead pushes into inflammation and oncology as it seeks to diversify beyond HIV franchise
    Gilead reported that HIV remained its strongest franchise in the second quarter, but the company is actively building a pipeline outside virology. CEO Daniel O’Day told investors that diversificat…
    BioSpace · 15d agoNeutral↗ source
  • Amgen drops Phase 1 obesity drug AMG 513, leaving MariTide as its only weight-loss candidate and eyes early-stage deals
    Amgen announced it is halting development of AMG 513, a Phase 1 obesity therapy, leaving MariTide as its sole weight‑loss asset. The company said its late‑stage pipeline is largely full, so future…
    BioSpace · 15d agoDealNeutral↗ source
  • Novo Nordisk CEO says innovation is essential as pipeline faces setbacks
    During Novo Nordisk's second-quarter earnings call, CEO Maziar Mike Doustdar said that failure is a normal part of drug development and emphasized that the company's survival depends on continual i…
    BioSpace · 15d agoEarningsNeutral↗ source
  • Merger talks between Bristol Myers Squibb and AstraZeneca fade as Q2 earnings roll out and FDA advisory meetings heat up
    Talks of a possible merger between Bristol Myers Squibb and AstraZeneca have receded after analysts highlighted antitrust hurdles. Both companies, each valued over $130 billion, were rumored to con…
    BioSpace · 15d agoDealNeutral↗ source
  • Five BioSpace NextGen companies debut on US markets in 2026, four actively hiring
    BioSpace NextGen honorees accounted for about one third of the 14 U.S. biotech companies that went public in 2026. The five companies together raised roughly $1.5 billion in IPO proceeds, includin…
    BioSpace · 15d agoPositive↗ source
  • Aurora Therapeutics drops PKU program and trims staff
    Aurora Therapeutics, a gene-editing startup founded by Jennifer Doudna, announced it is abandoning its lead phenylketonuria (PKU) program. The decision follows growing competition in the PKU field…
    BioSpace · 15d agoLayoffsNegative↗ source
  • AL Sydbank discloses share transactions by managers and related persons under MAR
    AL Sydbank issued a company announcement (No 41/2026) on 5 August 2026, informing the market of share transactions carried out by its managers and persons closely associated with them. The disclos…
    globenewswire health · 15d agoRegulatoryNeutral↗ source
  • Danske Bank corrects placement of English PDF in transaction disclosure
    The bank originally posted a notice that attached both the Danish and English PDF files to the Danish version of its website. A correction has now moved the English PDF to the English version of th…
    globenewswire health · 15d agoRegulatoryNeutral↗ source
  • Danske Bank corrects website link, moves English PDF to English page for shareholding report
    A correction notice was issued for Danske Bank A/S regarding the placement of an English PDF document on its website. The original announcement had both Danish and English PDFs attached under the…
    globenewswire health · 15d agoRegulatoryNeutral↗ source
  • Danske Bank corrects website to place English PDF with share buyback filing
    Danske Bank issued a correction notice stating that the English version of a PDF document has been relocated on its website. The amendment moves the English PDF from the Danish page to the dedicat…
    globenewswire health · 15d agoRegulatoryNeutral↗ source
  • AL Sydbank reports insider share transactions by senior staff and relatives
    AL Sydbank issued a market abuse regulation disclosure detailing share transactions by its senior employees and their close associates. The filing references attached tables that list the specific…
    globenewswire health · 15d agoNeutral↗ source
  • Danske Bank corrects webpage to place English transaction PDF under English version
    The bank has updated its online notification page so that the English PDF document is now attached under the English version of the site, rather than being listed only under the Danish version. Th…
    globenewswire health · 15d agoRegulatoryNeutral↗ source
  • AL Sydbank reports insider share transactions by senior staff and relatives
    AL Sydbank issued a corporate announcement on 5 August 2026, disclosing share transactions made by its senior employees and their close relatives. The disclosure is made in compliance with Article…
    globenewswire health · 15d agoRegulatoryNeutral↗ source
  • AL Sydbank reports manager and associate share transactions under Market Abuse Regulation
    AL Sydbank has issued a company announcement detailing recent share transactions carried out by its managers and individuals closely linked to them. The disclosure is made under Article 19 of the…
    globenewswire health · 15d agoRegulatoryNeutral↗ source
  • Danske Bank corrects webpage to place English PDF under English version for share buy-back disclosure
    A correction notice was issued for Danske Bank A/S regarding the placement of an English PDF on its website. The original posting had both Danish and English PDFs attached under the Danish version…
    globenewswire health · 15d agoNeutral↗ source
  • Danske Bank corrects webpage to place English PDF in English section
    A correction has been issued for a previous notification concerning Danske Bank A/S. The original posting attached both Danish and English PDF files under the Danish version of the page. The corre…
    globenewswire health · 15d agoNeutral↗ source